Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with Telaprevir

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Thomas, Xiomara V ^a   de Bruijne, Joep ^a   Sullivan, James C ^b   Kieffer, Tara L ^b   Ho, Cynthia K Y ^a   Rebers, Sjoerd P ^a   de Vries, Michel ^a   Reesink, Hendrik W ^a   Weegink, Christine J ^a   Molenkamp, Richard ^a   Schinkel, Janke ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 3 PROTEASE; PEGINTERFERON; PLACEBO; PROTEINASE; TELAPREVIR; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MONOTHERAPY; PATIENT CARE; PREVALENCE; PYROSEQUENCING; TREATMENT DURATION; ULTRA DEEP PYROSEQUENCING; VIRUS EXAMINATION; VIRUS MUTATION;

ADULT; AMINO ACID SUBSTITUTION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; OLIGOPEPTIDES; TIME FACTORS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 84864400361     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041191     Document Type: Article

References (33)

1. World Health Organization (2011) Hepatitis C. Fact sheet No. 164. Revised June 2011. Available: http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed 2012 Jan 23.
2. Terrault NA, Berenguer M,((2006)) Treating hepatitis C infection in liver transplant recipients. Liver Transpl 12:: 1192--120410.1002/lt.20865 [doi].
3. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, et al.((2003)) Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300: 1145--1148 10.1126/science.1082604 [doi];1082604 [pii].
4. Foster GR (2004) Past, present, and future hepatitis C treatments. Semin Liver Dis 24 (Suppl.2): 97-104. 10.1055/s-2004-832934 [doi].
5. McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM,((2006)) The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 44: 411-421. S0168-8278(05)00777-4 [pii];10.1016/j.jhep.2005.12.001 [doi].
6. Pawlotsky JM, McHutchison JG,((2004)) Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 39: 554-567. 10.1002/hep.20065 [doi].
7. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, et al.((2011)) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207-1217. 10.1056/NEJMoa1009482 [doi].
8. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al.((2011)) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206. 10.1056/NEJMoa1010494 [doi].
9. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, et al.((2007)) Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46: 640-648. 10.1002/hep.21774 [doi].
10. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van VA, et al.((2006)) Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131: 997-1002. S0016-5085(06)01539-3 [pii];10.1053/j.gastro.2006.07.013 [doi].
11. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al.((2011)) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416. 10.1056/NEJMoa1012912 [doi].
12. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al.((2011)) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-2428. 10.1056/NEJMoa1013086 [doi].
13. Bartenschlager R, Lohmann V,((2000)) Replication of hepatitis C virus. J Gen Virol 81:: 1631--1648.
14. Lin C, Lin K, Luong YP, Rao BG, Wei YY, et al.((2004)) In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 279: 17508-17514. 10.1074/jbc.M313020200 [doi];M313020200 [pii].
15. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, et al.((2007)) Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46: 631-639. 10.1002/hep.21781 [doi].
16. Sarrazin C, Zeuzem S,((2010)) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462. S0016-5085(09)02113-1 [pii];10.1053/j.gastro.2009.11.055 [doi].
17. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, et al.((2007)) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132: 1767-1777. S0016-5085(07)00394-0 [pii];10.1053/j.gastro.2007.02.037 [doi].
18. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, et al.((2007)) Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol 45: 1102-1112. JCM.02366-06 [pii];10.1128/JCM.02366-06 [doi].
19. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, et al.((1990)) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:: 495--503.
20. Nei M, Kumar S,((2000)) Molecular Evolution and Phylogenetics.New York: Oxford University Press.
21. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al.((2011)) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739. msr121 [pii];10.1093/molbev/msr121 [doi].
22. Li K, Venter E, Yooseph S, Stockwell TB, Eckerle LD, et al.((2010)) ANDES: Statistical tools for the ANalyses of DEep Sequencing. BMC Res Notes 3: 199. 1756-0500-3-199 [pii];10.1186/1756-0500-3-199 [doi].
23. Drummond AJ, Rambaut A, Shapiro B, Pybus OG,((2005)) Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol 22: 1185-1192. msi103 [pii];10.1093/molbev/msi103 [doi].
24. Drummond AJ, Ho SY, Phillips MJ, Rambaut A,((2006)) Relaxed phylogenetics and dating with confidence. PLoS Biol 4: e88. 05-PLBI-RA-0392R4 [pii];10.1371/journal.pbio.0040088 [doi].
25. Drummond AJ, Rambaut A,((2007)) BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 7: 214. 1471-2148-7-214 [pii];10.1186/1471-2148-7-214 [doi].
26. Strimmer K, Pybus OG,((2001)) Exploring the demographic history of DNA sequences using the generalized skyline plot. Mol Biol Evol 18:: 2298--2305.
27. Pybus OG, Rambaut A, Harvey PH,((2000)) An integrated framework for the inference of viral population history from reconstructed genealogies. Genetics 155:: 1429--1437.
28. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, et al.((2008)) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198: 800-807. 10.1086/591141 [doi].
29. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, et al.((2008)) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48: 1769-1778. 10.1002/hep.22549 [doi].
30. Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, et al.((2011)) Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One 6: e24907. 10.1371/journal.pone.0024907 [doi];PONE-D-11-11004 [pii].
31. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, et al.((2011)) Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol. S1386-6532(11)00342-8 [pii];10.1016/j.jcv.2011.08.015 [doi].
32. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, et al.((2009)) Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 4: e5683. 10.1371/journal.pone.0005683 [doi].
33. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, et al.((2012)) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366: 216-224. 10.1056/NEJMoa1104430 [doi].